Ampicillin is named as an intervention in 3 current clinical trials in our Spain, Canada and Israel registers. 2 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1). The most-studied condition is Endocarditis, Infective. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Ampicillin was first approved in the US on 29 Dec 1966.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.
NCT06423898 · ClinicalTrials.gov ↗ · Endocarditis, Infective
|
Phase 4 | Recruiting | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Spain |
|
Comparing Two Prophylactic Antibiotic Protocols in Women With Term Prolonged Pre-labor Rupture of Membrane and Preterm Labor
NCT05469984 · ClinicalTrials.gov ↗ · Preterm Labor With Preterm Delivery, Premature Rupture of Membranes Prolonged
|
Not applicable | Recruiting | Western Galilee Hospital-Nahariya | Israel |
|
NICU Antibiotics and Outcomes (NANO) Follow-up Study
NCT05977400 · ClinicalTrials.gov ↗ · Premature Birth, Antibiotics, Neurodevelopment
|
Phase 3 | Not yet open | Sharp HealthCare | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Ampicillin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Piperacillin/tazobactam or ampicillin and gentamicin for empirical treatment of community acquired infection: A randomised clinical trial (PAGER)
2026-526131-20-00 · Bacterial Infections and Mycoses
|
Phase 4 | Authorised | Region Hovedstaden | Denmark |
|
Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci
2026-526149-91-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Authorised | Friedrich-Schiller-Universitaet Jena | Germany |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
| Lead sponsor | Trials |
|---|---|
| Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 1 |
| Sharp HealthCare | 1 |
| Western Galilee Hospital-Nahariya | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in Israel | 1 | 1 |
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
3 current trials in our Spain, Canada and Israel registers name Ampicillin as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in Spain and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1), Sharp HealthCare (1) and Western Galilee Hospital-Nahariya (1). The number in brackets is how many trials each organisation leads.
The registers we track list 2 entries for Ampicillin: US FDA: resolved; 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ampicillin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ampicillin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ampicillin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.